Question-and-Answer Session
Operator
(Operator Instructions). Your first question comes from the line Bert Hazlett.
Bert Hazlett - BMO Capital Markets
Thanks for taking the question, good morning everybody. Could you just maybe elucidate a little bit better the status of the Opana ER discussions in Europe? And then could you discuss the terms that you're looking for with regard to partnering for Nalbuphone as well? Thanks.
Jennifer Good
Bert, the status in Europe, I mean it is making progress. I can't go into a lot of detail. I mean Endo has got active negotiations going on with a couple of parties; they are working through contract terms. I think it's getting close. There's no issues that I'm aware of that could derail it, it is just taking time. But I think it definitely made progress through the first quarter.
As far as the terms on Nalbuphine, we actually have it -- we are not at the point of talking terms with anybody yet. We're really out more soliciting interest. I think we're pretty open about how that deal looks with somebody.
I think our obvious need is to have a significant amount of that to be study funded, either through sort of their upfront involvement or somehow involved with that trial. But other than that, we are not really too fixated on anything. We just need to obviously minimize our cash into that program in '08.
Bert Hazlett - BMO Capital Markets
Okay. And just on another subject, Ben mentioned I believe the drug delivery partnerships as a potential event in 2008. Could you just talk a little bit more about that, what you mean by that? Are you looking for additional technologies or what is the extent of what you are looking for there?
Ben Palleiko
Yes, it's actually a revenue generator, Bert, as opposed to something you would spend money on. Last year we decided that we wanted to reinvigorate the efforts on doing licensing agreements where people get access to TIMERx technologies or maybe other ones we have for use in lifecycle management of existing products. And so what we've done is we've had our BD team out there talking to a number of companies about doing various different projects.
We signed one last year, as you may recall that was announced where we're doing am extended release version of an existing approved drug. And we continue to be very active in calling on companies and seeking other deals like this to set up. So currently we have several, three or four that are in active negotiations where folks have a need for an extended release version of the drug and they want us to license them TIMERx. And so what -- we get paid upfront in milestones as it develops and we also do the formulation work and then they take and do the clinical trials on them.
- To read the full transcript on Seeking Alpha, click here »
